- Home
- ZENV vs OPTN Comparison
ZENV vs OPTN Comparison
Compare ZENV & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- OPTN
- Stock Information
- Founded
- ZENV 2005
- OPTN 2010
- Country
- ZENV Brazil
- OPTN United States
- Employees
- ZENV N/A
- OPTN N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- ZENV Technology
- OPTN Health Care
- Exchange
- ZENV Nasdaq
- OPTN Nasdaq
- Market Cap
- ZENV 63.3M
- OPTN 78.4M
- IPO Year
- ZENV 2021
- OPTN 2017
- Fundamental
- Price
- ZENV $1.62
- OPTN $0.42
- Analyst Decision
- ZENV
- OPTN Strong Buy
- Analyst Count
- ZENV 0
- OPTN 3
- Target Price
- ZENV N/A
- OPTN $3.00
- AVG Volume (30 Days)
- ZENV 73.5K
- OPTN 924.6K
- Earning Date
- ZENV 11-18-2024
- OPTN 11-12-2024
- Dividend Yield
- ZENV N/A
- OPTN N/A
- EPS Growth
- ZENV N/A
- OPTN N/A
- EPS
- ZENV N/A
- OPTN N/A
- Revenue
- ZENV $173,594,726.00
- OPTN $75,672,000.00
- Revenue This Year
- ZENV $25.56
- OPTN $13.42
- Revenue Next Year
- ZENV $6.02
- OPTN $52.99
- P/E Ratio
- ZENV N/A
- OPTN N/A
- Revenue Growth
- ZENV 23.49
- OPTN 5.13
- 52 Week Low
- ZENV $1.00
- OPTN $0.32
- 52 Week High
- ZENV $3.88
- OPTN $2.10
- Technical
- Relative Strength Index (RSI)
- ZENV 54.93
- OPTN 35.42
- Support Level
- ZENV $1.61
- OPTN $0.39
- Resistance Level
- ZENV $1.78
- OPTN $0.57
- Average True Range (ATR)
- ZENV 0.12
- OPTN 0.05
- MACD
- ZENV -0.00
- OPTN -0.00
- Stochastic Oscillator
- ZENV 48.48
- OPTN 16.53
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create unique journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.